Aprocitentan Demonstrates Efficacy in Treatment-Resistant Hypertension: PRECISION Trial Results
Key Insights
The PRECISION trial, a phase 3 study, evaluated aprocitentan, a dual endothelin receptor antagonist (ERA), in patients with uncontrolled hypertension (search) despite triple antihypertensive therapy.
Aprocitentan significantly reduced systolic blood pressure compared to placebo in patients with resistant hypertension (search).
The multicenter, randomized trial included patients with systolic blood pressure of 140 mm Hg or higher despite treatment with three antihypertensive medications, including a diuretic.
Aprocitentan, a dual endothelin receptor antagonist (ERA), has shown promise in reducing systolic blood pressure in patients with treatment-resistant hypertension (search). The findings come from the phase 3 PRECISION trial, a multicenter, randomized study that evaluated the efficacy and safety of aprocitentan in individuals whose blood pressure remained elevated despite being on three antihypertensive drugs, including a diuretic.
The PRECISION trial enrolled patients with a systolic blood pressure of 140 mm Hg or higher, despite receiving treatment with three antihypertensive medications, one of which had to be a diuretic. The study aimed to determine if aprocitentan could provide additional blood pressure control in this difficult-to-treat population.
Endothelin is a potent vasoconstrictor, and blocking its receptors has been shown to lower blood pressure. Aprocitentan's mechanism of action, targeting both ETA and ETB receptors, may offer a more comprehensive approach to managing hypertension (search) compared to agents that only block one receptor subtype. The results of the PRECISION trial suggest that aprocitentan could be a valuable addition to the treatment armamentarium for patients with resistant hypertension, offering a new option for achieving blood pressure control and reducing cardiovascular risk.